Press Releases

Positive EBITDA in our ex-US business Fourth quarter 2025 January-December 2025 CEO comments Positive EBITDA in our ex-US business 2025 marked a successful year for Sedana Medical. We achieved first-time profitability in our core business outside the...

Sedana Medical AB (publ) plans to present its interim report for the fourth quarter of 2025 on Thursday February 12 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the fourth quarter 2025 on Thursday...

Sedana Medical AB (publ) announces the appointment of Mikael Haag as Chief Financial Officer (CFO) and member of the Executive Management Team. Mikael will assume his position no later than July 2026. Mikael is an accomplished finance executive with more...

Sedana Medical AB (publ) announces today that its CFO, Johan Spetz, has decided to leave the company to pursue a new career opportunity outside of the Life Science industry. Johan Spetz has held his position since March 2022. “Johan has been a key...

Sedana Medical AB (publ) announces that the company has completed its pre-NDA meeting with FDA and reached broad alignment with the Agency on the contents of the New Drug Application (NDA). FDA confirmed that safety and efficacy data from the clinical...

Improved EBITDA performance amid Q3 market headwinds Third quarter 2025 January-September 2025 CEO comments Improved EBITDA performance amid Q3 market headwinds In Q3, sales growth was modest at 7%, primarily reflecting very low ICU occupancy in several...

According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the Annual General Meeting 2026 shall be composed of members appointed by the three largest shareholders, along with...

Sedana Medical AB (publ) plans to present its interim report for the third quarter of 2025 on Friday October 24 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the third quarter 2025 on Friday...

Promising US data and strong sales growth in Q2 Second quarter 2025 January-June 2025 CEO comments Promising US data and strong sales growth in Q2 The first half of 2025 has been a successful period for Sedana Medical, with two record quarters in sales...

Sedana Medical AB (publ) announces that the results of the company’s paediatric study IsoCOMFORT (SED002) have been published in The Lancet Respiratory Medicine. “The publication in The Lancet Respiratory Medicine is a recognition for the...